$7,183.80 research Payment -- Johnson & Johnson to Dr. Gregory Evans

General Surgeon Gregory Evans Receives $7,183.80 Research Payment from Johnson & Johnson for Ocrevus

This page provides a detailed analysis of a $7,183.80 research payment from Johnson & Johnson to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$7,183.80
Payment Typeresearch
Payment NatureResearch
Pharmaceutical CompanyJohnson & Johnson
PhysicianDr. Gregory Evans
NPI Number1023707758
Physician SpecialtyGeneral Surgery
LocationCity, LA
Date of Payment2025-01-01
Related Drug/DeviceOcrevus
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Johnson & Johnson made a $7.2K research payment to Gregory Evans, a General Surgery specialist in City, LA. The payment was associated with Ocrevus. Gregory Evans received a $7,183.80 payment from Johnson & Johnson for research related to Ocrevus. The payment was made on January 1, 2025, indicating a recent research collaboration. This payment falls under the 'research' category, suggesting involvement in clinical trials or studies.

Patient Guidance: What This Payment Means for You

This payment is for research activities and may be related to studies involving the drug Ocrevus. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for research to General Surgeons can vary widely depending on the specific studies and the pharmaceutical company's research initiatives.

Regulatory Context: Sunshine Act Requirements

This payment is subject to disclosure under the Sunshine Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $7.2K payment for?

This was a research payment of $7.2K from Johnson & Johnson to Gregory Evans, categorized as "Research". It was associated with Ocrevus. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Gregory Evans accept pharmaceutical money?

Yes, Gregory Evans received this $7.2K payment from Johnson & Johnson. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $7.2K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in General Surgery?

To compare this payment against General Surgery averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. General Surgery physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Gregory Evans's relationship with Johnson & Johnson?

The payment amount is substantial, suggesting a significant research contribution. This $7.2K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for General Surgery?

The payment is specifically for 'research' activities, not for speaking or consulting.

What should patients do after learning about this payment?

This payment is for research activities and may be related to studies involving the drug Ocrevus.

What else should I know about this research payment?

Ocrevus is a drug used to treat multiple sclerosis, indicating the research focus.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.